Thursday, 28 September 2023



LATEST NEWS Div Com Ramesh Kumar reviews implementation of Govt Schemes, progress of Development works in Jammu District Get Ready to Roar with Laughter this Dussehra: 'Maujaan Hi Maujaan' Starring Gippy Grewal DC Ganderbal Shyambir presides over mega Grievance Redressal camp at Preng DC Ganderbal Shyambir reviews implementation of NEP 2020 in district Vijay Kumar Bidhuri takes departmental review of Employment, Social Welfare departments Vigilance Bureau Registers Case Against Dfsc, Two Inspectors, And Three Commission Agents For Misappropriation In Wheat Stocks Tourism Deptt Kulgam, Aharbal Development Authority observes ‘World Tourism Day’ Swachhta Hi Seva : RDD, Shopian conducts Cleanliness Drive at Ali-Abad Sarie, Peer Ki Gali JKEDI organizes Awareness program on Entrepreneurship & Startups for students of GD Goenka School Srinagar Punjab`S Nawan Pind Sardaran Baggs Best Tourism Village Of India-2023 Award DC Bandipora Dr. Owais Ahmad convenes meeting to finalize land, structures award for Ring Road Construction Block Diwas held in 3 blocks of Kulgam; DC Kulgam Dr. Bilal Mohi-Ud-Din Bhat listens issues of people for early redressal Tourism Department celebrates World Tourism day SKICC celebrates World Tourism Day Gold medalist of IDBF World Dragon Boat Championship, Coach calls on Secretary YSS Shabnam Kamili reviews arrangements for GI Mahotsav Lt Governor addresses seminar on great social reformer Swami Sahajanand at Ghazipur DC Poonch Yasin Mohammad Choudhary reviews ongoing Swachhata Hi Seva Campaign Block Diwas program held at 4 locations across Doda district DC Rajouri Vikas Kundal presides over Chintan Shivir at Khawas to pave the Way for implementation of Aspirational Block Program DEO Ramban Mussarat Islam chairs meeting of political representatives on rationalization of polling stations


New lung cancer pill cuts risk of death by half

Health, Study, New York, Research, Researchers, World News, American Society of Clinical Oncology, Asco
Listen to this article

Web Admin

Web Admin

5 Dariya News

New York , 05 Jun 2023

A new pill has shown promise of reducing the risk of death from lung cancer by half, according to results of a decade-long global clinical trial.Taking the drug osimertinib, developed by AstraZeneca, after surgery dramatically reduced the risk of patients dying by 51 per cent, showed results presented at the American Society of Clinical Oncology's (Asco) annual meeting in Chicago.

Osimertinib, which is marketed as Tagrisso, targets a particular type of lung cancer in patients suffering from non-small cell cancer -- the most common type -- and showing a particular type of mutation.Lung cancer is the world's leading cause of cancer death, accounting for about 1.8 million deaths a year.

"Thirty years ago, there was nothing we could do for these patients," said lead author Dr Roy Herbst, the deputy director of Yale Cancer Center, was quoted as saying by the Guardian. "Now we have this potent drug."Fifty per cent is a big deal in any disease, but certainly in a disease like lung cancer, which has typically been very resistant to therapies."

The trial involved patients aged between 30 and 86 in 26 countries and looked at whether the pill could help non-small cell lung cancer patients.Everyone in the trial had a mutation of the EGFR gene -- which is found in about a quarter of global lung cancer cases -- and accounts for as many as 40 per cent of cases in Asia. 

An EGFR mutation is more common in women than men, and in people who have never smoked or have been light smokers.As per the study's findings, more people diagnosed with lung cancer must be tested for the EGFR mutation

The pill proves to be "practice-changing" and should become the "standard of care" for the quarter of lung cancer patients worldwide with the EGFR mutation, Herbst said."This further reinforces the need to identify these patients with available biomarkers at the time of diagnosis and before treatment begins."

After five years, 88 per cent of patients who took the daily pill after the removal of their tumour were still alive, compared with 78 per cent of patients treated with a placebo, the report said.


Tags: Health , Study , New York , Research , Researchers , World News , American Society of Clinical Oncology , Asco



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2023 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD